Technical Analysis for RLMD - Relmada Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 5.52 | 1.85% | 0.10 |
RLMD closed up 1.85 percent on Monday, March 18, 2024, on 53 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 21
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Narrow Range Bar | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
50 DMA Support | Bullish | 1.85% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.85% | |
Outside Day | Range Expansion | 1.85% | |
Lower Bollinger Band Touch | Weakness | 1.85% | |
Oversold Stochastic | Weakness | 1.85% | |
New Downtrend | Bearish | 9.74% | |
Below Lower BB | Weakness | 9.74% | |
Gapped Down | Weakness | 9.74% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 20 hours ago |
Up 5% | about 20 hours ago |
Non-ADX 1,2,3,4 Pullback Entry | about 22 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Up 3% | about 22 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.2225 |
52 Week Low | 2.0 |
Average Volume | 232,289 |
200-Day Moving Average | 3.42 |
50-Day Moving Average | 4.88 |
20-Day Moving Average | 5.92 |
10-Day Moving Average | 5.84 |
Average True Range | 0.48 |
RSI (14) | 49.49 |
ADX | 40.86 |
+DI | 23.01 |
-DI | 23.03 |
Chandelier Exit (Long, 3 ATRs) | 5.79 |
Chandelier Exit (Short, 3 ATRs) | 6.24 |
Upper Bollinger Bands | 6.77 |
Lower Bollinger Band | 5.08 |
Percent B (%b) | 0.26 |
BandWidth | 28.40 |
MACD Line | 0.14 |
MACD Signal Line | 0.32 |
MACD Histogram | -0.1778 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.87 | ||||
Resistance 3 (R3) | 5.90 | 5.81 | 5.81 | ||
Resistance 2 (R2) | 5.81 | 5.73 | 5.80 | 5.79 | |
Resistance 1 (R1) | 5.67 | 5.67 | 5.74 | 5.64 | 5.77 |
Pivot Point | 5.58 | 5.58 | 5.62 | 5.57 | 5.58 |
Support 1 (S1) | 5.44 | 5.50 | 5.51 | 5.41 | 5.27 |
Support 2 (S2) | 5.35 | 5.44 | 5.34 | 5.25 | |
Support 3 (S3) | 5.21 | 5.35 | 5.23 | ||
Support 4 (S4) | 5.18 |